VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Sartorius Stedim Biotech S.A. vs Novartis AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Sartorius Stedim Biotech S.A.
DIM · Euronext Paris
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Sartorius Stedim Biotech S.A.'s moat claims, evidence, and risks.
View DIM analysisNovartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Novartis AG's moat claims, evidence, and risks.
View NOVN analysisComparison highlights
- Moat score gap: Sartorius Stedim Biotech S.A. leads (80 / 100 vs 65 / 100 for Novartis AG).
- Segment focus: Sartorius Stedim Biotech S.A. has 2 segments (75% in Sterile single-use bioprocessing consumables); Novartis AG has 5 segments (29.3% in Oncology).
- Moat breadth: Sartorius Stedim Biotech S.A. has 6 moat types across 3 domains; Novartis AG has 4 across 3.
Primary market context
Sartorius Stedim Biotech S.A.
Sterile single-use bioprocessing consumables
Sterile single-use bioprocessing consumables (bags, filters, fluid management components)
Global
Biopharmaceutical manufacturers and CDMOs
Consumables supplier (single-use)
75%
Novartis AG
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Global
Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels
Originator developer, manufacturer, and marketer of oncology therapies
29.3%
Side-by-side metrics
Moat coverage
Shared moat types
Sartorius Stedim Biotech S.A. strengths
Novartis AG strengths
Segment mix
Sartorius Stedim Biotech S.A. segments
Full profile >Sterile single-use bioprocessing consumables
Oligopoly
Bioprocessing equipment, systems, and software/services
Oligopoly
Novartis AG segments
Full profile >Cardiovascular, Renal and Metabolic
Oligopoly
Immunology
Oligopoly
Neuroscience
Oligopoly
Oncology
Oligopoly
Established Brands
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.